| Timeframe | Predicted Price | Past | Historical | Insight |
|---|---|---|---|---|
| Tomorrow | $67.74 ▼ -0.97% | Yesterday | $68.69 ▲ +0.41% | Tomorrow's Halozyme Therapeutics Inc. Common Stock (HALO) setup is anchored to $68.41 and targets $67.74 (-0.97%). The near-term read is downside; watch $70.46 / $66.36 because daily realized volatility is about 5.01%. |
Tomorrow's Halozyme Therapeutics Inc. Common Stock (HALO) setup is anchored to $68.41 and targets $67.74 (-0.97%). The near-term read is downside; watch $70.46 / $66.36 because daily realized volatility is about 5.01%. | ||||
| Week | $66.34 ▼ -3.02% | Last Week | $69.28 ▲ +1.27% | The 7-day Halozyme Therapeutics Inc. Common Stock model moves from $69.28 to $66.34 (-3.02%). It gives downside momentum context for this stock, so breaks around $70.46 / $66.36 matter more than a single tick. |
The 7-day Halozyme Therapeutics Inc. Common Stock model moves from $69.28 to $66.34 (-3.02%). It gives downside momentum context for this stock, so breaks around $70.46 / $66.36 matter more than a single tick. | ||||
| Month | $64.00 ▼ -6.44% | Last Month | $70.26 ▲ +2.71% | The 1-month Halozyme Therapeutics Inc. Common Stock target is $64.00 (-6.44%), compared with the live reference near $68.41. This horizon blends current trend pressure with price momentum, liquidity, and company-specific risk. |
The 1-month Halozyme Therapeutics Inc. Common Stock target is $64.00 (-6.44%), compared with the live reference near $68.41. This horizon blends current trend pressure with price momentum, liquidity, and company-specific risk. | ||||
| Year | $60.50 ▼ -11.57% | Last Year | $71.73 ▲ +4.86% | The 1-year Halozyme Therapeutics Inc. Common Stock scenario points to $60.50 (-11.57%). Confidence is lower than short-term rows, so treat it as cycle context and re-check it after major market-data updates. |
The 1-year Halozyme Therapeutics Inc. Common Stock scenario points to $60.50 (-11.57%). Confidence is lower than short-term rows, so treat it as cycle context and re-check it after major market-data updates. | ||||
| 5 Years | $52.28 ▼ -23.57% | 5 Years Ago | $75.18 ▲ +9.90% | The 5-year Halozyme Therapeutics Inc. Common Stock view is $52.28 (-23.57%). It is a directional scenario built from bounded drift and volatility, not a guaranteed path. |
The 5-year Halozyme Therapeutics Inc. Common Stock view is $52.28 (-23.57%). It is a directional scenario built from bounded drift and volatility, not a guaranteed path. | ||||
| Indicator | Value | Signal |
|---|---|---|
| Price | $68.41 | Mid |
| Daily Change | -1.67% | Below |
| Volatility Cap | 20.0% | Mid |
| Confidence | 61% | Below |
| Data Source | nasdaq-screener | Mid |
| Current | $68.41 | Daily Change | -1.67% |
| Market Cap | $8.10B | Source | nasdaq-screener |
Related ideas for internal navigation, grouped by stronger upside and weaker downside setups in the same market.